Amifostine reduces inflammation and protects against 5-fluorouracil-induced oral mucositis and hyposalivation

Barbosa, S C M; Pereira, V B M; Wong, D V T; Santana, A P M; Lucetti, L T; Carvalho, L L; Barbosa, C R N; Callado, R B; Silva, C A A; Lopes, C D H; Brito, G A C; Alencar, N M N; Lima-Júnior, R C P.
Braz. j. med. biol. res ; 52(3): e8251, 2019. tab, graf
Artigo em Inglês | LILACS | ID: biblio-984035

Documentos relacionados

  1. Amifostine reduces inflammation and protects against 5-fluorouracil-induced oral mucositis and hyposalivation.
  2. Oral conditions and salivary analysis in HIV-uninfected subjects using preexposure prophylaxis.
  3. Rationale for integrating high-dose rate intraoperative radiation (HDR-IORT) and postoperative external beam radiation with subcutaneous amifostine for the management of stage III/IV head and neck cancer.
  4. Amifostine reduces side effects and improves complete response rate during radiotherapy: results of a meta-analysis.
  5. Intravenous amifostine during chemoradiotherapy for head-and-neck cancer: a randomized placebo-controlled phase III study.
  6. Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy.
  7. Insufficient evidence for interventions to prevent dry mouth and salivary gland dysfunction post head and neck radiotherapy.
  8. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer.
  9. Goji Berry Juice Prevents Tumor Necrosis Factor Alpha-Induced Xerostomia in Human Salivary Gland Cells.
  10. Prevention and treatment options for medication-induced xerostomia.